A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
Clinical trial NCT05976243 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05976243
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-07
- Primary completion
- 2026-05-11
- Enrollment
- 362
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.